Synonym
Emraclidine, CVL-231; CVL 231; CVL231; PF-06852231; PF 06852231; PF06852231;
IUPAC/Chemical Name
1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-{1-[2-(trifluoromethyl)pyridin-4-yl]azetidin-3-yl}ethan-1-one
InChi Key
DTCZNKWBDTXEBS-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H21F3N4O/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14H,6,8-11H2,1-2H3
SMILES Code
O=C(N1CC2=NC(C)=CC(C)=C2C1)CC3CN(C4=CC(C(F)(F)F)=NC=C4)C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
390.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. PMID: 36528376.
2: Cookson J, Jonsson F. A new cholinergic mechanism for antipsychotics: emraclidine and M4 muscarinic receptors. Lancet. 2022 Dec 17;400(10369):2159-2161. doi: 10.1016/S0140-6736(22)02421-7. PMID: 36528365.
3: Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel Compounds in the Treatment of Schizophrenia-A Selective Review. Brain Sci. 2023 Aug 11;13(8):1193. doi: 10.3390/brainsci13081193. PMID: 37626549; PMCID: PMC10452918.
4: Naguy A, Pridmore S, Alamiri B. The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So! Psychopharmacol Bull. 2023 Feb 28;53(1):55-57. PMID: 36873922; PMCID: PMC9981338.
